Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 14/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.47 |
| ▸ | FAP | Q12884 | 3/20 | 0.47 |
| ▸ | PREP | P48147 | 2/20 | 0.47 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111112 | 1.00 | DPP4 (0.47) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL1951493 | 1.00 | DPP4 (0.47) | DPP4DPP7DPP8DPP9FAP | |
| Hydrochloric Acid SCHEMBL25318201 | 0.98 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP | |
| Hydrochloric Acid SCHEMBL9512282 | 0.98 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL19982029 | 0.98 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL15203539 | 0.98 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL2735523 | 0.98 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP | |
| Hydrochloric Acid SCHEMBL9512271 | 0.98 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL9102765 | 0.95 | DPP4 (0.47) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL9102749 | 0.95 | DPP4 (0.47) | DPP4DPP7DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | claimed |
| EP-2550273-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | claimed |
| US-20230234956-A1 | METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20230234956-A1 | METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2023-07-27 | — | — | US | disclosed |
| EP-2440558-B1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL (JP) | 2015-04-01 | — | — | EP | disclosed |
| EP-2440558-B1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL (JP) | 2015-04-01 | — | — | EP | disclosed |
| US-8980322-B2 | Controlled release composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8785429-B2 | Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2014-07-22 | — | — | US | disclosed |
| US-8785429-B2 | Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2014-07-22 | — | — | US | disclosed |
| US-8785429-B2 | Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2014-07-22 | — | — | US | disclosed |
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110136780-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110136780-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110086096-A1 | MODIFIED RELEASE 1- [ (3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL] -PYRROLIDINE-2 (S) -CARBONITRILE FORMULATION | KOWALSKI JAMES | 2011-04-14 | — | — | US | disclosed |
| WO-2010144486-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-16 | — | — | WO | disclosed |
| EP-2191824-A1 | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation | Novartis AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20100021539-A1 | Modified Release 1-[(3-Hydroxy-Adamant-1-Ylamino)-Acetyl]-Pyrrolidine-2(S)-Carbonitrile Formulation | KOWALSKI JAMES | 2010-01-28 | — | — | US | disclosed |
| EP-1898904-B1 | MODIFIED RELEASE 1-[(3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL]-PYRROLIDINE-2(S)-CARBONITRILE FORMULATION | NOVARTIS AG (CH) | 2009-10-07 | — | — | EP | disclosed |
| US-20060177509-A1 | Controlled release composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1607088-A1 | CONTROLLED RELEASE COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2005-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086096-A1 | MODIFIED RELEASE 1- [ (3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL] -PYRROLIDINE-2 (S) -CARBONITRILE FORMULATION | MAST1, CACNG1, CMA1 | DPP4 267/4885DPP7 525/4885DPP8 1048/4885 |
| US-20230234956-A1 | METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS | WEE1, WEE2, CCNE1 | DPP4 4422/4885DPP7 4022/4885DPP8 3956/4885 |
| US-20110136780-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | JAK2, JAK1, JAK3 | DPP4 1869/4885DPP7 1377/4885DPP8 2881/4885 |
| US-20100021539-A1 | Modified Release 1-[(3-Hydroxy-Adamant-1-Ylamino)-Acetyl]-Pyrrolidine-2(S)-Carbonitrile Formulation | MAST1, CMA1, SUCNR1 | DPP4 195/4885DPP7 463/4885DPP8 907/4885 |
| US-20060177509-A1 | Controlled release composition | ATP6AP1, NSF, ATP6V1G1 | DPP4 2445/4885DPP7 2048/4885DPP8 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.